Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : GLAXF save search
Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone
Published: 2023-03-27 (Crawled : 23:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 3.17%
H: 0.0%
C: 0.0%
GSK | $39.685 1.06% 380K
|
Health Technology
|
| O: 0.26%
H: 0.17%
C: -0.09%
ANAB | $19.98 0.76% 60K
|
Health Technology
|
| O: 0.23%
H: 0.36%
C: -1.59%
cancer treatment trial plus potential
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
GLAXF | $20.2 510
|
Health Technology
|
| O: -1.01%
H: 0.0%
C: -2.13%
GSK | $39.685 1.06% 380K
|
Health Technology
|
| O: -1.54%
H: 0.91%
C: 0.14%
sdc-1801 application trial update
GSK showcases progress from the DREAMM clinical trial program in multiple myeloma at the 2021 ASH Annual Meeting
Published: 2021-11-18 (Crawled : 13:30) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: -6.25%
H: 3.09%
C: -0.45%
GSK | $39.685 1.06% 380K
|
Health Technology
|
| O: -1.66%
H: 0.24%
C: -0.12%
trial
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
GLAXF | $20.2 510
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -0.31%
GSK | $39.685 1.06% 380K
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
VIR | $8.02 0.75% 140K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
covid treatment phase 3 trial
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.